ClinicalTrials.gg
CompletedNCT00903175RECORD-3Updated Nov 8, 2016Results posted

Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

A Phase 2 interventional study of everolimus and sunitinib in Renal Cell Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 84 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
471
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 49 studies testing everolimus in Carcinoma, Renal Cell — 4 open to participants now, 7 under way, 2 of them phase 3. Everolimus · Carcinoma, Renal Cell.

Enrollment
3rd of 49
471 · median 43
Started
2009
with 4 others
Phase 2
27 of 49
2 open now
Registered
17th of 49
by date
Lead sponsor
9 of 49
Novartis Pharmaceuticals

Among the 49 studies testing everolimus in Carcinoma, Renal Cell, this one is the 3rd largest by enrollment, is one of 5 that started in 2009, is one of 27 in phase 2, and was the 17th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

4 of the 49 studies testing everolimus in Carcinoma, Renal Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing everolimus in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • RAD001
  • everolimus
  • sunitinib
  • renal cell carcinoma
  • kidney cancer
  • metastatic renal cell cancer
  • advanced kidney cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with advanced renal cell carcinoma.
  2. Patients with at least one .
  3. Patients with a Performance Status ≥70%.
  4. Adequate bone marrow function.
  5. Adequate liver function.
  6. Adequate renal function.
  7. (LVEF) ≥ lower limit of institutional normal (LLN)
  8. Women of must have had a negative serum pregnancy test within 14 days prior to the administration of the study medication. Adequate must be used while on study.

Exclusion criteria

Exclusion Criteria:

  1. Less than 4 weeks post-major surgery
  2. Patients who had radiation therapy within 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed within 2 weeks prior to study treatment start).
  3. Patients in need for major surgical procedure during the course of the study
  4. Patients with a serious non-healing wound, ulcer, or bone fracture
  5. Patients with a history of seizure(s) not controlled with standard medical therapy
  6. Patients who have received prior systemic treatment for their RCC
  7. Patients who have previously received systemic mTOR inhibitors (sirolimus, temsirolimus, everolimus) or VEGF inhibitors. Note: History of immunotherapy, vaccines or adjuvant sorafenib following localized surgical nephrectomy is acceptable.
  8. Patients with a known to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins or to its excipients
  9. Patients with a known hypersensitivity to sunitinib or its excipients
  10. History or clinical evidence of central nervous system (CNS) metastases. Note: Subjects who have previously-treated (surgery plus or minus radiotherapy, radiosurgery, or gamma knife) and meet all 3 of the following criteria are eligible:

    • Are asymptomatic and,
    • have had no evidence of active CNS metastases for ≥ 6 months prior to enrollment and,
    • have no requirement for or enzyme-inducing anticonvulsants (EIAC)
  11. gastrointestinal abnormalities including, but not limited to:

    • Malabsorption syndrome
    • Major resection of the stomach or small bowel that could affect the absorption of study drug
    • Active peptic ulcer disease
    • Inflammatory bowel disease
    • Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation
    • History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment.
  12. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥160mmHg or diastolic blood pressure (DBP) of ≥ 95mmHg]
  13. Patients receiving chronic systemic treatment with corticosteroids or another agent
  14. Patients with a known history of seropositivity.
  15. Patients with active bleeding.
  16. Patients who have any severe and/or uncontrolled medical conditions or other conditions within the past 12 months that could affect their participation in the study such as:

    • Cardiac angioplasty or stenting, unstable angina pectoris, symptomatic peripheral vascular disease, symptomatic congestive heart failure ( II, III, IV), myocardial infarction ≤ 6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia, cerebrovascular accidents ≤ 6 months before study treatment start.
    • Prolongation of interval (QTc) > 500 milliseconds (msecs).
    • Severally impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 0\^2 saturation that is 88% or less at rest on room air.
    • Poorly controlled diabetes as defined by fasting serum glucose >2.0 x .
    • Any active (acute or chronic) or uncontrolled infection/disorders that impair the ability to evaluate the patient or for the patient to complete the study.
    • Liver disease such as chronic active hepatitis or chronic persistent hepatitis.
  17. History of cerebrovascular accident (CVA) including (TIA).
  18. History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.
  19. Patients who have a history of another primary and off treatment for ≤ 3 years
  20. Female patients of who are not using adequate methods, or who are pregnant or breast feeding.
  21. Patients who are using other agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
  22. Patients unwilling or unable to comply with the protocol.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
471 participants (actual)

Study arms

  • Experimental
    everolimus 1L/sunitinib 2L

    everolimus First Line: 10 mg orally, once daily, (two 5 mg tablets), continuous treatment. sunitinib Second Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2)

    Drug: everolimus · Drug: sunitinib

  • Active comparator
    sunitinib 1L/everolimus 2L

    sunitinib First Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2) everolimus Second Line: 10 mg orally, once daily (two 5 mg tablets), continuous treatment

    Drug: everolimus · Drug: sunitinib

Interventions

  • Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.

    Also known as: RAD001

  • Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival First-Line (PFS 1-L)

    PFS_1L based on investigator assessment of radiology data by RECIST 1.0, was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause during or after first-line treatment with everolimus or sunitinib. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: based on radiological assessments every 3 months until disease progression, start of another antineoplastic therapy or for any other reason up to 35 months

Secondary outcomes

  1. Progression-free Survival Combined (PFS-C)

    PFS-C (1L and 2L study drugs combined) was a composite endpoint which combined both lines of study treatment. It was defined as the time from the date of randomization to the first of the following: date of death due to any cause, or date of the first radiologically documented progression disease during or after the second-line treatment period for patients with a radiologically documented progression disease in the first-line treatment period and who had crossed-over to second-line treatment no more than 6 weeks after progression.

    Time frame: based on radiological assessments every 3 months until disease progression, start of another antineoplastic therapy or for any other reason up to about 56 months

  2. Overall Survival (OS)

    Overall survival was defined as the time from date of randomization to date of death due to any cause. The analysis of OS included all deaths in the FAS regardless of when they were observed.

    Time frame: Every 2 months from randomization up to 3 years after last patient randomized

  3. Overall Response Rate (ORR) - First -Line (1-L)

    ORR was defined as the number of participants with best overall response (BOR) of complete response (CR) or partial response (PR) and was based on investigator assessment of radiology data per RECIST. Participants with best overall response of 'Unknown' were treated as non-responders in the calculation of the ORR. Confirmed CR = at least two determinations of CR at least 4 weeks apart before progression. Confirmed PR = at least two determinations of PR or better at least 4 weeks apart before progression. CR required a disappearance of all target and non-target lesions. PR required at least a 30% decrease in the sum of the longest diameters of all target lesions, taking as a reference the baseline sum of the longest diameters. Radiological assessments : every 12 weeks until disease progression, the start of another antineoplastic therapy or for any other reason.

    Time frame: based on radiological assessments every 3 months until disease progression, start of another antineoplastic therapy or for any other reason up to 35 months

  4. Duration of Response (DoR) - First-Line (1-L)

    Duration of overall response (CR or PR) applies only to patients whose Best Overall Response (BOR) was Complete Response (CR) or Partial Response (PR) during the first-line treatment period. The start date was the date of first documented response (CR or PR) during the first-line treatment and the end date was the date of the event defined as the first documented progression or death due to underlying cancer during or after the same treatment line.

    Time frame: based on radiological assessments every 3 months until disease progression, start of another antineoplastic therapy or for any other reason up to 35 months

  5. Time to Definitive Deterioration of the FKSI-DRS Risk Score by at Least 3 Score Units by First-line Drug

    The Functional Assessment of Cancer Therapy - Kidney Symptom Index, Disease Related Symptoms (FKSI-DRS) is a set of items to assess symptoms experienced by patients with advanced kidney cancer. These symptoms include fatigue, pain, weight loss, dyspnea, cough, fever and hematuria. Each item is scored on a 5-point scale (0 = not at all; 4 = very much). The FKSI-DRS total score ranges from 0 (most severe symptoms) to 36 (no symptoms). Definitive deterioration was defined as a decrease by at least 3 units compared to baseline, with no later increase above this threshold observed during the 1-L of treatment. A single measure reporting a decrease of at least 3 units was considered definitive only if it was the last one available for the patient.

    Time frame: <=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months

  6. Time to Definitive Deterioration of the FKSI-DRS Risk Score by at Least 3 Score Units by First and Second-line Drugs Combined

    The Functional Assessment of Cancer Therapy - Kidney Symptom Index, Disease Related Symptoms (FKSI-DRS) is a set of items to assess symptoms experienced by patients with advanced kidney cancer. These symptoms include fatigue, pain, weight loss, dyspnea, cough, fever and hematuria. Each item is scored on a 5-point scale (0 = not at all; 4 = very much). The FKSI-DRS total score ranges from 0 (most severe symptoms) to 36 (no symptoms). Definitive deterioration was defined as a decrease by at least 3 units compared to baseline, with no later increase above this threshold observed during the 1-L or 2-L treatment. A single measure reporting a decrease of at least 3 units was considered definitive only if it was the last one available for the patient.

    Time frame: <=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months

  7. Time to Definitive Deterioration of the Physical Functioning (PF) Scale of the EORTC QLQ-C30 - by First-Line (1L) Drug

    The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items. The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line of treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

    Time frame: <=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months

  8. Time to Definitive Deterioration of the Physical Functioning Scale of the EORTC QLQ-C30 - by First and Second-Line Drugs Combined

    The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items.The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line or second line treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

    Time frame: <=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months

  9. Time to Definitive Deterioration of the Global Health Status/QoL Scores of the EORTC QLQ-C30 by First-Line Drug

    The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items.The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line of treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

    Time frame: <=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months

  10. Time to Definitive Deterioration of the Global Health Status/QoL Scores of the EORTC QLQ-C30 by First and Second-Line Drugs Combined

    The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items. The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line or second line treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

    Time frame: <=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months

  11. Time to Definitive Deterioration of the Fatigue Scale of the EORTC QLQ-C30 by First-Line Drug

    The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items.The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line of treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

    Time frame: <=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months

  12. Time to Definitive Deterioration of the Fatigue Scale of the EORTC QLQ-C30 by First and Second-Line Drugs Combined

    The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items. The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line or second line treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

    Time frame: <=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months

07

Results

Posted Jun 28, 2016
Limitations and caveats
PRO Tools - completed on Days 1 \& 28 of a cycle. Assessments on D1 coincided with end of a 14-day break for patients on sunitinib but not everolimus. So D1 assessments of patients in sunitinib arm may be less impacted by potential toxicity effects.

Participant flow

238 patients were randomized to everolimus as 1st line followed by 2nd line sunitinib. All patients in this group were treated. 233 patients were randomized to the sunitinib as 1st line followed by 2nd line everolimus. However 2 of the 233 patients were not treated in this group.

Period 1 - First Line
Participant flow — Period 1 - First Line
MilestoneEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Started238231
Completed161142
Not completed7789
Withdrew: Adverse event3650
Withdrew: Abnormal lab value(s)01
Withdrew: Abnormal test procedure result(s)10
Withdrew: Protocol violation33
Withdrew: Withdrawal by subject812
Withdrew: Administrative problems1213
Withdrew: Death1710
Period 2 - Second Line
Participant flow — Period 2 - Second Line
MilestoneEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Started128116
Completed7980
Not completed4936
Withdrew: Missing10
Withdrew: Adverse event1620
Withdrew: Withdrawal by subject75
Withdrew: Lost to follow-up10
Withdrew: Administrative problems199
Withdrew: Death52

Outcome measures

PrimaryProgression Free Survival First-Line (PFS 1-L)

PFS_1L based on investigator assessment of radiology data by RECIST 1.0, was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause during or after first-line treatment with everolimus or sunitinib. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
based on radiological assessments every 3 months until disease progression, start of another antineoplastic therapy or for any other reason up to 35 months
Reported as:
Median · Months
Progression Free Survival First-Line (PFS 1-L)
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Progression Free Survival First-Line (PFS 1-L)7.85 (5.55 to 8.25)10.71 (8.18 to 11.53)
Statistical analysis
  • Everolimus 1L/Sunitinib 2L vs Sunitinib 1L/Everolimus 2L · Hazard ratio (hr): 1.43 · 95% CI 1.15 to 1.77
SecondaryProgression-free Survival Combined (PFS-C)

PFS-C (1L and 2L study drugs combined) was a composite endpoint which combined both lines of study treatment. It was defined as the time from the date of randomization to the first of the following: date of death due to any cause, or date of the first radiologically documented progression disease during or after the second-line treatment period for patients with a radiologically documented progression disease in the first-line treatment period and who had crossed-over to second-line treatment no more than 6 weeks after progression.

Time frame:
based on radiological assessments every 3 months until disease progression, start of another antineoplastic therapy or for any other reason up to about 56 months
Reported as:
Median · Months
Progression-free Survival Combined (PFS-C)
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Progression-free Survival Combined (PFS-C)21.68 (15.05 to 26.71)22.18 (16.03 to 29.83)
SecondaryOverall Survival (OS)

Overall survival was defined as the time from date of randomization to date of death due to any cause. The analysis of OS included all deaths in the FAS regardless of when they were observed.

Time frame:
Every 2 months from randomization up to 3 years after last patient randomized
Reported as:
Median · Months
Overall Survival (OS)
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Overall Survival (OS)22.41 (18.60 to 33.28)29.47 (22.83 to 33.05)
SecondaryOverall Response Rate (ORR) - First -Line (1-L)

ORR was defined as the number of participants with best overall response (BOR) of complete response (CR) or partial response (PR) and was based on investigator assessment of radiology data per RECIST. Participants with best overall response of 'Unknown' were treated as non-responders in the calculation of the ORR. Confirmed CR = at least two determinations of CR at least 4 weeks apart before progression. Confirmed PR = at least two determinations of PR or better at least 4 weeks apart before progression. CR required a disappearance of all target and non-target lesions. PR required at least a 30% decrease in the sum of the longest diameters of all target lesions, taking as a reference the baseline sum of the longest diameters. Radiological assessments : every 12 weeks until disease progression, the start of another antineoplastic therapy or for any other reason.

Time frame:
based on radiological assessments every 3 months until disease progression, start of another antineoplastic therapy or for any other reason up to 35 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) - First -Line (1-L)
percentage of participantsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Complete Response (CR)13
Partial Response (PR)1859
Overall Response Rate (CR + PR)1962
SecondaryDuration of Response (DoR) - First-Line (1-L)

Duration of overall response (CR or PR) applies only to patients whose Best Overall Response (BOR) was Complete Response (CR) or Partial Response (PR) during the first-line treatment period. The start date was the date of first documented response (CR or PR) during the first-line treatment and the end date was the date of the event defined as the first documented progression or death due to underlying cancer during or after the same treatment line.

Time frame:
based on radiological assessments every 3 months until disease progression, start of another antineoplastic therapy or for any other reason up to 35 months
Reported as:
Median · Months
Duration of Response (DoR) - First-Line (1-L)
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Duration of Response (DoR) - First-Line (1-L)13.37 (8.3 to NA)17.25 (11.4 to NA)
SecondaryTime to Definitive Deterioration of the FKSI-DRS Risk Score by at Least 3 Score Units by First-line Drug

The Functional Assessment of Cancer Therapy - Kidney Symptom Index, Disease Related Symptoms (FKSI-DRS) is a set of items to assess symptoms experienced by patients with advanced kidney cancer. These symptoms include fatigue, pain, weight loss, dyspnea, cough, fever and hematuria. Each item is scored on a 5-point scale (0 = not at all; 4 = very much). The FKSI-DRS total score ranges from 0 (most severe symptoms) to 36 (no symptoms). Definitive deterioration was defined as a decrease by at least 3 units compared to baseline, with no later increase above this threshold observed during the 1-L of treatment. A single measure reporting a decrease of at least 3 units was considered definitive only if it was the last one available for the patient.

Time frame:
<=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months
Reported as:
Median · Months
Time to Definitive Deterioration of the FKSI-DRS Risk Score by at Least 3 Score Units by First-line Drug
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Time to Definitive Deterioration of the FKSI-DRS Risk Score by at Least 3 Score Units by First-line Drug12.65 (7.9 to 19.4)16.66 (13.7 to NA)
SecondaryTime to Definitive Deterioration of the FKSI-DRS Risk Score by at Least 3 Score Units by First and Second-line Drugs Combined

The Functional Assessment of Cancer Therapy - Kidney Symptom Index, Disease Related Symptoms (FKSI-DRS) is a set of items to assess symptoms experienced by patients with advanced kidney cancer. These symptoms include fatigue, pain, weight loss, dyspnea, cough, fever and hematuria. Each item is scored on a 5-point scale (0 = not at all; 4 = very much). The FKSI-DRS total score ranges from 0 (most severe symptoms) to 36 (no symptoms). Definitive deterioration was defined as a decrease by at least 3 units compared to baseline, with no later increase above this threshold observed during the 1-L or 2-L treatment. A single measure reporting a decrease of at least 3 units was considered definitive only if it was the last one available for the patient.

Time frame:
<=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months
Reported as:
Median · Months
Time to Definitive Deterioration of the FKSI-DRS Risk Score by at Least 3 Score Units by First and Second-line Drugs Combined
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Time to Definitive Deterioration of the FKSI-DRS Risk Score by at Least 3 Score Units by First and Second-line Drugs Combined14.23 (12.0 to 19.4)15.97 (13.7 to 20.4)
SecondaryTime to Definitive Deterioration of the Physical Functioning (PF) Scale of the EORTC QLQ-C30 - by First-Line (1L) Drug

The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items. The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line of treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

Time frame:
<=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months
Reported as:
Median · Months
Time to Definitive Deterioration of the Physical Functioning (PF) Scale of the EORTC QLQ-C30 - by First-Line (1L) Drug
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Time to Definitive Deterioration of the Physical Functioning (PF) Scale of the EORTC QLQ-C30 - by First-Line (1L) Drug13.47 (7.9 to 20.6)14.03 (12.1 to 17.7)
SecondaryTime to Definitive Deterioration of the Physical Functioning Scale of the EORTC QLQ-C30 - by First and Second-Line Drugs Combined

The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items.The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line or second line treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

Time frame:
<=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months
Reported as:
Median · Months
Time to Definitive Deterioration of the Physical Functioning Scale of the EORTC QLQ-C30 - by First and Second-Line Drugs Combined
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Time to Definitive Deterioration of the Physical Functioning Scale of the EORTC QLQ-C30 - by First and Second-Line Drugs Combined12.25 (9.5 to 16.3)14.03 (12.0 to 17.7)
SecondaryTime to Definitive Deterioration of the Global Health Status/QoL Scores of the EORTC QLQ-C30 by First-Line Drug

The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items.The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line of treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

Time frame:
<=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months
Reported as:
Median · Months
Time to Definitive Deterioration of the Global Health Status/QoL Scores of the EORTC QLQ-C30 by First-Line Drug
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Time to Definitive Deterioration of the Global Health Status/QoL Scores of the EORTC QLQ-C30 by First-Line Drug7.92 (5.6 to 12.1)12.25 (7.9 to 14.1)
SecondaryTime to Definitive Deterioration of the Global Health Status/QoL Scores of the EORTC QLQ-C30 by First and Second-Line Drugs Combined

The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items. The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line or second line treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

Time frame:
<=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months
Reported as:
Median · Months
Time to Definitive Deterioration of the Global Health Status/QoL Scores of the EORTC QLQ-C30 by First and Second-Line Drugs Combined
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Time to Definitive Deterioration of the Global Health Status/QoL Scores of the EORTC QLQ-C30 by First and Second-Line Drugs Combined10.84 (7.5 to 13.8)12.71 (10.5 to 14.8)
SecondaryTime to Definitive Deterioration of the Fatigue Scale of the EORTC QLQ-C30 by First-Line Drug

The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items.The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line of treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

Time frame:
<=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months
Reported as:
Median · Months
Time to Definitive Deterioration of the Fatigue Scale of the EORTC QLQ-C30 by First-Line Drug
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Time to Definitive Deterioration of the Fatigue Scale of the EORTC QLQ-C30 by First-Line Drug9.20 (6.2 to 12.6)11.37 (9.3 to 13.4)
SecondaryTime to Definitive Deterioration of the Fatigue Scale of the EORTC QLQ-C30 by First and Second-Line Drugs Combined

The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items. These include a global health status/QoL scale, five functional scales, three symptom scales, and six single items. The standardized score for the PF, fatigue subscales and global health status ranges from 0 to 100, with a higher score representing a high level of functioning/high level of symptom/high quality of life. Definitive deterioration by at least 10% was defined as a decrease in score by at least 10% compared to baseline, with no later increase above this threshold observed during the first line or second line treatment. A single measure reporting a decrease of at least 10% was considered definitive only if it was the last one available for the participant.

Time frame:
<=14 days prior to the first dose of study medication, on day 1, day 28 of every cycle, at the end of treatment visit, at the 28 day FUP visit and monthly thereafter for up to 3 months or until initiation of another anticancer therapy up to 35 months
Reported as:
Mean · Months
Time to Definitive Deterioration of the Fatigue Scale of the EORTC QLQ-C30 by First and Second-Line Drugs Combined
MonthsEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
Time to Definitive Deterioration of the Fatigue Scale of the EORTC QLQ-C30 by First and Second-Line Drugs Combined11.56 (7.9 to 14.1)13.34 (10.8 to 15.9)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus 1L/Sunitinib 2L—139/238 (58.4%)231/238 (97.1%)
Sunitinib 1L/Everolimus 2L—131/231 (56.7%)228/231 (98.7%)
Most frequent serious events
Showing 10 of 284
Most frequent serious events
EventEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
PneumoniaInfections and infestations18/23815/231
AnaemiaBlood and lymphatic system disorders16/2389/231
DyspnoeaRespiratory, thoracic and mediastinal disorders12/23813/231
DehydrationMetabolism and nutrition disorders13/2386/231
Pleural effusionRespiratory, thoracic and mediastinal disorders10/23812/231
Acute kidney injuryRenal and urinary disorders11/23810/231
PyrexiaGeneral disorders10/2387/231
ThrombocytopeniaBlood and lymphatic system disorders2/2389/231
Abdominal painGastrointestinal disorders6/2388/231
VomitingGastrointestinal disorders5/2388/231
Most frequent other events
Showing 10 of 105
Most frequent other events
EventEverolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2L
StomatitisGastrointestinal disorders134/238146/231
DiarrhoeaGastrointestinal disorders131/238140/231
FatigueGeneral disorders124/238131/231
NauseaGastrointestinal disorders114/238125/231
Decreased appetiteMetabolism and nutrition disorders93/238101/231
CoughRespiratory, thoracic and mediastinal disorders96/23876/231
RashSkin and subcutaneous tissue disorders95/23867/231
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders46/23892/231
HypertensionVascular disorders61/23884/231
Oedema peripheralGeneral disorders79/23858/231

Baseline characteristics

The Full Analysis Set (FAS) consists of all randomized patients. Following the intent-to-treat principle, patients are analyzed according to the treatment sequence and stratum they were assigned to at randomization.

Age, Continuous
Age, Continuous(years)Everolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2LTotal
Mean61.36 ± 12.10260.84 ± 11.62761.10 ± 11.860
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Everolimus 1L/Sunitinib 2LSunitinib 1L/Everolimus 2LTotal
Female7257129
Male166176342
08

Study locations

84 sites
  • University of Alabama at Birmingham/ Kirklin Clinic Comprehensive CancerCenter (1)
    Birmingham, Alabama 35294-0006, United States
  • University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst.
    Mobile, Alabama 36688, United States
  • Highlands Oncology Group HighlandsOncGrp-Bentonville(2)
    Fayetteville, Arkansas 72703, United States
  • University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (5)
    La Jolla, California 92093-0658, United States
  • University of California at Los Angeles Dept. of UCLA (3)
    Los Angeles, California 90095, United States
  • University of Colorado Dept. of Anschutz Cancer (2)
    Aurora, Colorado 80045, United States
  • Norwalk Hospital Norwlak SC
    Norwalk, Connecticut 06856, United States
  • Georgetown University/Lombardi Cancer Center Dept.of Lombardi Cancer Ctr (2
    Washington, District of Columbia 20007-2197, United States
  • Lynn Cancer Institute
    Boca Raton, Florida 33486, United States
  • University of Miami SC
    Miami, Florida 33136, United States
  • MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando
    Orlando, Florida 32806, United States
  • University Cancer & Blood Center, LLC Dept of NE GCC (2)
    Athens, Georgia 30607, United States
  • Georgia Health Sciences University Dept. of MCG
    Augusta, Georgia 30912, United States
  • Summit Cancer Care
    Savannah, Georgia 31405, United States
  • NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept.ofNorthwesternMemHospital
    Chicago, Illinois 60611, United States
  • Loyola University Medical Center /Cardinal Bernardin Cancer Cardinal Bernardin Cancer (3)
    Maywood, Illinois 60153, United States
  • Crescent City Research Consortium, LLC SC
    Metairie, Louisiana 70006, United States
  • VA Maryland Health Care Dept.of GreenbaumCancerCent(7)
    Baltimore, Maryland 21201, United States
  • Weinberg Cancer Institute at Franklin Square Hospital
    Baltimore, Maryland 21237-3998, United States
  • Billings Clinic Dept of Billings Clinic(2)
    Billings, Montana 59107, United States
  • Hackensack University Medical Center DeptofHackensackUniv.MedCtr.
    Hackensack, New Jersey 07601, United States
  • Cooper Cancer Center
    Voorhees, New Jersey 08043, United States
  • Clinical Research Alliance
    Lake Success, New York 11042, United States
  • Memorial Sloan Kettering Cancer Center Dept. of MSKCC
    NY, New York 10065, United States
  • SUNY - Upstate Medical University Div. of Hematology-Oncology
    Syracuse, New York 13210, United States
  • University of North Carolina Dept. of LinbergerCancerCtr(3)
    Chapel Hill, North Carolina 27599-7295, United States
  • Levine Cancer Institute Oncology
    Charlotte, North Carolina 28203, United States
  • Duke University Medical Center Duke
    Durham, North Carolina 27710, United States
  • University of Oklahoma Health Sciences Center Dept of OHSC
    Oklahoma City, Oklahoma 73104, United States
  • St. Luke's Hospital and Health Network St Luke's Hospital (2)
    Bethlehem, Pennsylvania 18015, United States
  • The West Clinic Dept. of the West Clinic
    Memphis, Tennessee 38120, United States
  • The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2)
    Fort Worth, Texas 76104, United States
  • East Texas Medical Center Cancer Institute
    Tyler, Texas 75701, United States
  • Utah Cancer Specialists Dept.of Utah Cancer Spec. (3)
    Salt Lake City, Utah 84106, United States
  • Aurora Advanced Healthcare SC
    Milwaukee, Wisconsin 53215, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1405BCH, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires B1902CMK, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2002KDS, Argentina
  • Novartis Investigative Site
    Tucuman, T4000IAK, Argentina
  • Novartis Investigative Site
    Woodville, South Australia 5011, Australia
  • Novartis Investigative Site
    Rio de Janeiro, RJ 20230-130, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 90610-000, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 05403-000, Brazil
  • Novartis Investigative Site
    Calgary, Alberta T2N 4N2, Canada
  • Novartis Investigative Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Novartis Investigative Site
    Victoria, British Columbia V8R 6V5, Canada
  • Novartis Investigative Site
    Toronto, Ontario M4N 3M5, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2X 3J4, Canada
  • Novartis Investigative Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Novartis Investigative Site
    Herlev, DK-2730, Denmark
  • Novartis Investigative Site
    Angers cedex 02, 49055, France
  • Novartis Investigative Site
    Lille Cedex, 59020, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Vandoeuvre-Les-Nancy Cede, 54511, France
  • Novartis Investigative Site
    Aschaffenburg, 63739, Germany
  • Novartis Investigative Site
    Berlin, 10098, Germany
  • Novartis Investigative Site
    Weiden, 92637, Germany
  • Novartis Investigative Site
    Hongkong, Hong Kong
  • Novartis Investigative Site
    Shatin, New Territories, Hong Kong
  • Novartis Investigative Site
    Arezzo, AR 52100, Italy
  • Novartis Investigative Site
    Modena, MO 41100, Italy
  • Novartis Investigative Site
    Napoli, 80132, Italy
  • Novartis Investigative Site
    Seoul, Korea 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 03722, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 05505, Korea, Republic of
  • Novartis Investigative Site
    Daejeon, 301-747, Korea, Republic of
  • Novartis Investigative Site
    Chihuahua, 31000, Mexico
  • Novartis Investigative Site
    Den Haag, 2545 CH, Netherlands
  • Novartis Investigative Site
    Maastricht, 6229 HX, Netherlands
  • Novartis Investigative Site
    Jesus Maria, Lima 11, Peru
  • Novartis Investigative Site
    Elche, Alicante 03203, Spain
  • Novartis Investigative Site
    Sevilla, Andalucia 41013, Spain
  • Novartis Investigative Site
    Sabadell, Barcelona 08208, Spain
  • Novartis Investigative Site
    Lleida, Cataluna 25198, Spain
  • Novartis Investigative Site
    Taipei, Taiwan, ROC 112, Taiwan
  • Novartis Investigative Site
    Niaosong Township, 83301, Taiwan
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Istanbul, 34093, Turkey
  • Novartis Investigative Site
    Bristol, Avon BS2 8ED, United Kingdom
  • Novartis Investigative Site
    London, SW3 6JJ, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Publications

  • Voss MH, Chen D, Reising A, Marker M, Shi J, Xu J, Ostrovnaya I, Seshan VE, Redzematovic A, Chen YB, Patel P, Han X, Hsieh JJ, Hakimi AA, Motzer RJ. PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clin Cancer Res. 2019 Jan 15;25(2):506-514. doi: 10.1158/1078-0432.CCR-18-1833. Epub 2018 Oct 16. PubMed 30327302 ↗
  • Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 2017 Jun 1;28(6):1339-1345. doi: 10.1093/annonc/mdx075. Erratum In: Ann Oncol. 2018 Nov 1;29(11):2269. doi: 10.1093/annonc/mdx807. PubMed 28327953 ↗
  • Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014 Sep 1;32(25):2765-72. doi: 10.1200/JCO.2013.54.6911. Epub 2014 Jul 21. PubMed 25049330 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2009
First posted
May 18, 2009
Start
Oct 2009
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Jun 28, 2016
Last update
Nov 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00903175
Responsible party
Sponsor
First posted
May 18, 2009
Start date
Oct 2009
Primary completion
May 2015
Completion
May 2015
Results posted
Jun 28, 2016
Last update
Nov 8, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Everolimus · Sunitinib

Start the discussion